WHY NOVUS CAPITAL?Novus Capital Limited is an investment and financial services company specialising in Investment Banking, Corporate Advisory and Share Trading services for Australian corporate and private clients, and overseas corporate clients.
October 2nd, 2024
Electrogenics Laboratories Limited (“ELL”) or (the Company) owns the granted patents and has a worldwide exclusive license from the University of Wollongong (UoW) for the MOSkin sensor technology. The MOSkin technology was developed by a team at the Centre for Medical Radiation Physics (CMRP) at the UoW led by Professor Anatoly Rozenfeld. Under his leadership, the CMRP at UoW is regarded as one of the world's leading institutes of Medical Radiation Physics.
These types of radiation sensors are used during Radiation treatment mainly for cancers but also for interventional radiology procedures such as angiograms.
MOSkin technology, among other things, is the only sensor technology that can measure radiation dosage compliant with the WED 0.7mm recommended standard. This standard is currently a guideline (because up until now no one could meet it) but may become mandatory in Europe in the next few years and, thereafter, will most likely be adopted worldwide.
ELL is now very advanced in preparing its FDA submission to gain approval to sell its MOSkin Dosimeter system in the USA. The submission is targeted for the end of October/November this year. Classified as a Class II medical device, MOSkin™ has also qualified for the accelerated 510k approval pathway. Products of this nature on the 510k pathway have well over a 90% approval rate, and the median approval time is between 90 and 120 days.
In anticipation of that approval, the Company is now seeking funding to finance the initial commercialisation of MOSkin™ in the United States. This will include purchasing initial inventory, hiring marketing and distribution professionals, and finding, vetting, appointment, and training specialist medical distributors.
The Company is offering a limited opportunity for eligible investors to participate in its Series C raise, the details of which are:
There will be a further pre-IPO raise after the FDA approval, which is expected in Q1 2025. The price is expected to be two to three times the current price, but, as always, there can be no guarantees.
IPO is planned for Q3/4 2025 after establishing a sales record in the USA. The Company may also consider M&A opportunities should they deliver outsized returns for the shareholders.
Click on the picture to download the Deal Summary Sheet.
or Contact Gavan Farley - Deal Lead
gavan.farley@novuscapital.com.au
+61 420 520 300
